Y-mAbs Therapeutics Inc (YMAB)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Thomas Gad
Employees:
150
750 THIRD AVENUE, 9TH FLOOR, NEW YORK, NY 10017
212-847-9841

Y-mAbs Therapeutics, Inc. focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment of cancer in the United States. The company is developing DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor. GD2-GD3 vaccine that is in Phase II clinical trial for the. treatment of Stage 4 high-risk neuroblastoma.

Data derived from most recent annual or quarterly report
Market Cap 132.751 Million Shares Outstanding43.668 Million Avg 30-day Volume 313.082 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.63
Price to Revenue27.0211 Debt to Equity0.0 EBITDA-99.162 Million
Price to Book Value9.4698 Operating Margin-216.6605 Enterprise Value1.111 Billion
Current Ratio5.227 EPS Growth0.702 Quick Ratio4.784
1 Yr BETA 1.7343 52-week High/Low 20.48 / 2.7 Profit Margin-83.2048
Operating Cash Flow Growth11.9523 Altman Z-Score17.8174 Free Cash Flow to Firm -82.325 Million
View SEC Filings from YMAB instead.

View recent insider trading info

Y-mAbs Therapeutics Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding YMAB (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding YMAB

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-01-30 by LISBY STEEN
  • 4: filed on 2023-01-30 by LUND-HANSEN TORBEN
  • 4: filed on 2023-01-30 by RAJAH VIGNESH
  • 4: filed on 2023-01-30 by SMITH SUSAN LAURA
  • 4: filed on 2023-01-30 by WILMS JORIS
  • 4: filed on 2023-01-19 by RAJAH VIGNESH
  • 4: filed on 2023-01-19 by LUND-HANSEN TORBEN
  • 4: filed on 2023-01-19 by GAD THOMAS
  • 4: filed on 2023-01-19 by SMITH SUSAN LAURA
  • 4: filed on 2023-01-19 by LISBY STEEN

    • Events (8k)

  • 8-K: filed on 2023-03-13:
    Item 8.01: Other Events
  • 8-K: filed on 2023-02-02:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-01-04:
    Item 2.02: Results of Operations and Financial Condition
    Item 2.05: Cost Associated with Exit or Disposal Activities
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-12-21:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-12-16:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-12-14:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-12-08:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-12-02:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-07:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-10-28:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    LUND-HANSEN TORBEN SVP & CHIEF TECHNICAL OFFICER

    • Officer
    		 32,000 2023-01-26 3

    LISBY STEEN SVP & CHIEF SCIENTIFIC OFFICER

    • Officer
    		 32,000 2023-01-26 3

    WILMS JORIS SVP & CHIEF OPERATING OFFICER

    • Officer
    		 32,000 2023-01-26 3

    RAJAH VIGNESH SVP & CHIEF MEDICAL OFFICER

    • Officer
    		 32,000 2023-01-26 4

    SMITH SUSAN LAURA SVP & CHIEF COMMERCIAL OFFICER

    • Officer
    		 32,000 2023-01-26 3

    KRUSE BO EVP, CFO, SECRY & TREAS.

    • Officer
    		 262,877 2023-01-17 2

    GAD THOMAS SEE REMARKS

    • Officer
    • Director
    		 715,532 2023-01-17 2

    GILL DAVID N

    • Director
    		 16,000 2022-07-15 1

    HEALY JAMES

    • Director
    		 16,000 2022-07-15 1

    HAMILL LAURA

    • Director
    		 16,000 2022-07-15 1

    TYAGI ASHU

    • Director
    		 16,000 2022-07-15 1

    WEDELL-WEDELLSBORG JOHAN

    • Director
    		 16,000 2022-07-15 1

    BER GERARD

    • Director
    		 16,000 2022-07-15 1

    MOLLER-SAN PEDRO CLAUS JUAN DIRECTOR AND CEO

    • Officer
    • Director
    		 230,000 2021-12-14 0

    WG BIOTECH APS

    • Director
    • SEE REMARKS
    		 4,178,456 2021-06-10 0

    HERMAN PHILIP KARL SVP & CCO

    • Officer
    		 0 2020-12-15 0

    AHMED MAHIUDDIN SR. VP AND CSO

    • Officer
    		 150,000 2020-05-26 0

    RASKIN GREGORY S

    • Director
    		 0 2019-08-29 0

    BUSCHLE MICHAEL

    • Director
    		 0 2018-09-20 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    WILMS JORIS - Officer SVP & CHIEF OPERATING OFFICER

    		2023-01-30 16:31:17 -0500 2023-01-26 A 32,000 a 32,000 direct

    LISBY STEEN - Officer SVP & CHIEF SCIENTIFIC OFFICER

    		2023-01-30 16:35:08 -0500 2023-01-26 A 32,000 a 32,000 direct

    LUND-HANSEN TORBEN - Officer SVP & CHIEF TECHNICAL OFFICER

    		2023-01-30 16:34:14 -0500 2023-01-26 A 32,000 a 32,000 direct

    RAJAH VIGNESH - Officer SVP & CHIEF MEDICAL OFFICER

    		2023-01-30 16:33:16 -0500 2023-01-26 A 32,000 a 32,000 direct

    SMITH SUSAN LAURA - Officer SVP & CHIEF COMMERCIAL OFFICER

    		2023-01-30 16:32:10 -0500 2023-01-26 A 32,000 a 32,000 direct

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    Y-MABS THERAPEUTICS INC YMAB 2023-03-24 22:15:03 UTC 4.263 0.557 450000
    Y-MABS THERAPEUTICS INC YMAB 2023-03-24 21:45:03 UTC 4.263 0.557 450000
    Y-MABS THERAPEUTICS INC YMAB 2023-03-24 21:15:03 UTC 4.263 0.557 450000
    Y-MABS THERAPEUTICS INC YMAB 2023-03-24 20:45:03 UTC 4.263 0.557 450000
    Y-MABS THERAPEUTICS INC YMAB 2023-03-24 20:15:04 UTC 4.263 0.557 450000
    Y-MABS THERAPEUTICS INC YMAB 2023-03-24 19:45:03 UTC 4.263 0.557 450000
    Y-MABS THERAPEUTICS INC YMAB 2023-03-24 19:15:04 UTC 4.263 0.557 450000
    Y-MABS THERAPEUTICS INC YMAB 2023-03-24 18:45:04 UTC 4.263 0.557 450000
    Y-MABS THERAPEUTICS INC YMAB 2023-03-24 18:15:03 UTC 4.263 0.557 450000
    Y-MABS THERAPEUTICS INC YMAB 2023-03-24 17:45:03 UTC 4.263 0.557 450000
    Y-MABS THERAPEUTICS INC YMAB 2023-03-24 17:15:03 UTC 4.263 0.557 450000
    Y-MABS THERAPEUTICS INC YMAB 2023-03-24 16:45:03 UTC 4.072 0.748 450000
    Y-MABS THERAPEUTICS INC YMAB 2023-03-24 16:15:03 UTC 4.072 0.748 250000
    Y-MABS THERAPEUTICS INC YMAB 2023-03-24 15:45:03 UTC 4.0652 0.7548 250000
    Y-MABS THERAPEUTICS INC YMAB 2023-03-24 15:15:03 UTC 4.0652 0.7548 500000
    Y-MABS THERAPEUTICS INC YMAB 2023-03-24 14:45:03 UTC 4.0652 0.7548 500000
    Y-MABS THERAPEUTICS INC YMAB 2023-03-24 14:15:03 UTC 4.0652 0.7548 250000
    Y-MABS THERAPEUTICS INC YMAB 2023-03-24 13:45:03 UTC 3.5963 0.9738 250000
    Y-MABS THERAPEUTICS INC YMAB 2023-03-24 13:15:04 UTC 3.5963 0.9738 250000
    Y-MABS THERAPEUTICS INC YMAB 2023-03-24 12:45:03 UTC 3.5963 0.9738 250000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    Trust for Professional Managers- Convergence Market Neutral Fund YMAB -1607.0 shares, $-69149.21 2020-08-31 N-PORT
    FundVantage Trust- Gotham Enhanced Index Plus Fund YMAB -66.0 shares, $-1722.6 2020-03-31 N-PORT
    FundVantage Trust- Gotham Index Plus All-Cap Fund YMAB -69.0 shares, $-1800.9 2020-03-31 N-PORT
    Weiss Strategic Interval Fund- Weiss Strategic Interval Fund YMAB -5800.0 shares, $-83636.0 2022-09-30 N-PORT
    RUSSELL INVESTMENT FUNDS- U.S. Small Cap Equity Fund YMAB -1940.0 shares, $-9467.2 2022-12-31 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments